ResearchPDF Available

Green-lipped mussel and curcumin in mobility foods for dogs

Authors:

Abstract

Green-lipped mussel and curcumin in mobility foods for dogs Mobility impairment is a common canine disease. Dogs are reluctant to walk, run and jump, and may show lameness. The cause often is breakdown of cartilage in joints. This implies loss of shock absorber that allows the joint to move smoothly. The ends of the bones begin to rub together, evoking pain. Damaged tissue elicits the release of inflammatory substances, contributing to pain and swelling of the joint. The condition is called osteoarthritis. There are dog foods, snacks and nutritional supplements making joint-health claims, whereas therapeutic mobility foods purport to reduce clinical signs of osteoarthritis. These products are marketed on the basis of a wide variety of joint-protective constituents. Among these agents are powders derived from the New-Zealand green-lipped mussel and preparations of curcumin, which is a component of the yellow spice made from turmeric stem. For demonstration of the efficacy of a potential joint-improving agent, a double-blinded, placebo-controlled trial in dogs with osteoarthritis is required. The placebo has no real effect and treatment identity is kept from both owner and investigator. In this way, the trial design takes into account the impact, if any, of biased evaluation and spontaneous course of disease. In placebo-treated dogs with osteoarthritis there often is perceived improvement over time. Studies on the efficacy of green-lipped mussel either had inadequate design or unconvincing results for its application in the management of canine osteoarthritis. There is no comfortable evidence that mobility foods containing either green-lipped mussel or curcumin reduce clinical signs of osteoarthritis in dogs. Green-lipped mussel and curcumin Powdered preparations and oily extracts of the New Zealand green-lipped mussel (Perna canaliculus) have anti-inflammatory properties in model systems. In-vitro studies indicate that curcuminoid derivatives reduce inflammation and inhibit collagen degradation in cartilage. Thus, there are clues to a beneficial effect of green-lipped mussel and curcumin in the treatment of canine osteoarthritis, but solid evidence can only come from well-designed clinical trials. Trials on green-lipped mussel Oral administration of a green-lipped mussel preparation reportedly improved clinical signs in arthritic dogs (1), but the study was open and non-controlled. Putting green-lipped mussel powder on top of food or incorporating it into a treat significantly improved dogs' arthritis scores over 6 weeks (2). The dose was equivalent to 139 mg/MJ of metabolizable energy as calculated for a 35-kg dog. The two experiments were designated as double-blind and controlled, but no control topping was used and it is uncertain whether the control and test treats were indistinguishable. Moreover, the magnitude of the effects can be considered meaningless.
Creature Companion 2016; June: 54-55.
Anton C. Beynen
Green-lipped mussel and curcumin in mobility foods for dogs
Mobility impairment is a common canine disease. Dogs are reluctant to walk, run and jump, and
may show lameness. The cause often is breakdown of cartilage in joints. This implies loss of shock
absorber that allows the joint to move smoothly. The ends of the bones begin to rub together,
evoking pain. Damaged tissue elicits the release of inflammatory substances, contributing to pain
and swelling of the joint. The condition is called osteoarthritis.
There are dog foods, snacks and nutritional supplements making joint- health claims, whereas
therapeutic mobility foods purport to reduce clinical signs of osteoarthritis. These products are
marketed on the basis of a wide variety of joint-protective constituents. Among these agents are
powders derived from the New-Zealand green-lipped mussel and preparations of curcumin, which
is a component of the yellow spice made from turmeric stem.
For demonstration of the efficacy of a potential joint-improving agent, a double-blinded, placebo-
controlled trial in dogs with osteoarthritis is required. The placebo has no real effect and
treatment identity is kept from both owner and investigator. In this way, the trial design takes into
account the impact, if any, of biased evaluation and spontaneous course of disease. In placebo-
treated dogs with osteoarthritis there often is perceived improvement over time.
Studies on the efficacy of green-lipped mussel either had inadequate design or unconvincing
results for its application in the management of canine osteoarthritis. There is no comfortable
evidence that mobility foods containing either green-lipped mussel or curcumin reduce clinical
signs of osteoarthritis in dogs.
Green-lipped mussel and curcumin
Powdered preparations and oily extracts of the New Zealand green-lipped mussel (Perna canaliculus)
have anti-inflammatory properties in model systems. In-vitro studies indicate that curcuminoid
derivatives reduce inflammation and inhibit collagen degradation in cartilage. Thus, there are clues
to a beneficial effect of green-lipped mussel and curcumin in the treatment of canine osteoarthritis,
but solid evidence can only come from well-designed clinical trials.
Trials on green-lipped mussel
Oral administration of a green-lipped mussel preparation reportedly improved clinical signs in
arthritic dogs (1), but the study was open and non-controlled. Putting green-lipped mussel powder
on top of food or incorporating it into a treat significantly improved dogs’ arthritis scores over 6
weeks (2). The dose was equivalent to 139 mg/MJ of metabolizable energy as calculated for a 35-kg
dog. The two experiments were designated as double-blind and controlled, but no control topping
was used and it is uncertain whether the control and test treats were indistinguishable. Moreover,
the magnitude of the effects can be considered meaningless.
In a double-blinded, placebo-controlled study, oral delivery of green-lipped mussel extract (53
mg/MJ for 12 weeks) did not affect clinical signs in dogs with osteoarthritis (3). Another masked and
controlled trial showed that ingestion of freeze-dried green-lipped mussel (139 mg/MJ for 8 weeks)
significantly improved mobility (4). The median improvement versus baseline was 1 on a 0-24 scale
and 0.2 on a 0-10 scale for the assessment by veterinarians and owners, respectively. This calls into
question the clinical relevance of the statistically significant increase in mobility.
A double-blinded, placebo-controlled trial concluded that oral treatment with a green-lipped mussel
extract (139 mg/MJ for 8 weeks) improved the arthritis score in dogs with osteoarthritis (5), but the
baseline scores for control and test group were different, whereas the negative slopes of the score
time courses were similar. In an open, non-controlled study, the intake of green-lipped mussel oil
was associated with less lameness in dogs with osteoarthritis (6).
Trials on curcumin
A complex mixture including curcumin (7) and an extract of two turmeric species (8) have been
evaluated in canine osteoarthritis. The extract (17 mg curcumin plus desmethoxycurcumin/MJ for 8
weeks) was tested in a double-blind, placebo-controlled trial (8). The investigators’ and owners’
overall assessments were in favor of curcumin, but lameness, pain on joint manipulation and kinetic
gait pattern appeared unaffected. A high proportion (19/24) of curcumin-treated dogs emanated
malodor through their skin, urine or feces. This effect may have compromised the blinded nature of
the study.
Therapeutic mobility foods
Three studies (2, 9-11) have addressed the efficacy of a therapeutic mobility food containing green-
lipped mussel. The kibbles were coated with freeze-dried powder at a final inclusion level of 0.3% (2,
9, 10). One study was open and uncontrolled (10). The other two studies were blinded, but had a
longitudinal instead of parallel control (2, 9, 11) so that time effects cannot be excluded. An
improvement of the dogs’ arthritic scores was claimed (2, 9). Apart from the flawed study design,
the improvement was 4 on a 0-196 scale, which is clinically irrelevant.
Dogs suffering from osteoarthritis were fed a therapeutic food supplemented with curcuminoids
extract, hydrolysed collagen and green tea extract for 3 months (12). Clearly, curcumin was not the
sole additive. The study was named double-blinded and placebo-controlled, but effective blinding is
questionable. Curcumin probably colored the test food yellow, stained the owners’ hands and
caused dogs to generate malodor. The therapeutic diet diminished some kinds of pain, but did not
improve lameness and mobility. The study is wrongly cited in substantiation of the food’s advertising
slogan: “Visible improvements to mobility, activity and quality of life” (13).
Literature
1. Korthäuer W, De la Torre J. Behandlung deformierender Arthopathien beim Diensthund mit einem
neuen Glykosaminoglykanpräparat. Kleintierpraxis 1992; 37: 467-478.
2. Bierer TL, Bui LM. Improvement of arthritic signs in dogs fed green-lipped mussel (Perna
canaliculus). J Nutr 2002; 132: 1634S-1636S.
3. Dobenecker B, Beetz Y, Kienzle E. A placebo-controlled double-blind study on the effect of
nutraceuticals (chondoitin sulfate and mussel extract) in dogs with joint disease as perceived by their
owners. J Nutr 2002; 132: 1690S-1691S.
4. Hielm-Björkman A, Tulamo R-M, Salonen H, Raekillio M. Evaluating complementary therapies for
canine osteoarthritis Part I: Green-lipped mussel (Perna canaliculus). eCAM 2009; 6: 365-373.
5. Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficacy and tolerance of an
extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with
degenerative joint disease. N Z Vet J 2006; 54: 114-118.
6. Mongkon N, Soontornvipart K. Preliminary study of the clinical outcome of of using PCO-524
polyunsaturated fatty acid compound in the treatment of canine osteoarthritis and degenerative
spinal diseases. Thai J Vet Med 2012; 42: 311-317.
7. Moreau M, Lussier B, Pelletier J-P, Martel-Pelletier J, Bédard C, Gauvin D, Troncy E. A medicinal
herb-based natural health product improves the condition of a canine natural osteoarthritis model:
A randomized placebo-controlled trial. Res Vet Sci 2014; 97: 574-581.
8. Innes JF, Fuller CJ, Grover ER, Kelly AL, Burn JF. Randomised, double-blind, placebo-controlled
parallel group study of P54FP for the treatment of dogs with osteoarthritis. Vet Rec 2003; 152: 457-
460.
9. Bui LM, Bierer TL. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of
arthritis in dogs. Vet Therapeutics 2003; 4: 397-407.
10. Servet E, Biourge V, Marniquet P. Dietary intervention can improve clinical signs in osteoarthritic
dogs. J Nutr 2006; 136: 1995S-1997S.
11. Rialland P, Bichot S, Lussier B, Moreau M, Beaudry F, Del Castillo JRE, Gauvin D, Troncy E. Effect
of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical
osteoarthritis. Can J Vet Res 2013; 77: 66-74.
12. Comblain F, Barthélémy N, Lefebvre M, Schwartz C, Lesponne I, Serisier S, Feugier A, Balligand M,
Henrotin Y. Randomized, double-blinded, controlled clinical trial evaluating the efficacy of a diet
supplemented with curcuminoids extract, hydrolyzed collagen and green tea extract in dogs
suffering from osteoarthritis. Osteoarthritis Cart 2016; 24: S353.
13. Advertisement (A leap forward in mobility management). Vet Pract 2015; 47(9): 5.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
An oral herb-based natural health product (NHP) was evaluated in the canine natural osteoarthritis model. At Baseline, the peak vertical force (PVF, primary endpoint) and case-specific outcome measure of disability (CSOM) were recorded in privately-owned dogs. Dogs (16/group) were randomized to receive NHP formulations or a negative control. The PVF was measured at week (W) 4 and W8. Daily locomotor activity was recorded using accelerometer. The CSOMs were assessed bi-weekly by the owner. The NHP-treated dogs (n=13) had higher PVF at W4 (p=0.020) and W8 (p<0.001) when compared to Baseline. The changes at W8 were higher than control dogs (n=14, p<0.027) and consistent with a Cohen's d effect size of 0.7 (95% confidence interval: 0.0 to 1.5). The NHP-treated dogs had higher locomotor activity at W8 (p=0.025) when compared to Baseline. No significant change was observed for the CSOM. The NHP improved the clinical signs of osteoarthritis in this model.
Article
Full-text available
This study aimed to establish the effect of a diet enriched with green-lipped mussel (GLM) on pain and functional outcomes in osteoarthritic dogs. Twenty-three client-owned dogs with osteoarthritis (OA) were fed a balanced control diet for 30 d and then a GLM-enriched balanced diet for the next 60 d. We assessed peak vertical force (PVF), which is considered to be the gold standard method, at Day (D)0 (start), D30 (end of control diet), and D90 (end of GLM-enriched diet). The owners completed a client-specific outcome measure (CSOM), which is a pain questionnaire, once a week. Motor activity (MA) was continuously recorded in 7 dogs for 12 wk. Concentrations of plasma omega-3 fatty acids were quantified as indicative of diet change. Statistical analyses were linear-mixed models and multinomial logistic regression for repeated measures. The GLM diet (from D30 to D90) resulted in an increase in concentrations of plasma omega-3 fatty acids (P < 0.016) and improvement of PVF (P = 0.003). From D0 to D30, PVF did not significantly change (P = 0.06), which suggests that the GLM diet had a beneficial effect on gait function. Moreover, PVF (P = 0.0004), CSOM (P = 0.006), and MA (P = 0.02) improved significantly from D0 to D90. In general, the balanced control diet could have contributed to reduced OA symptoms, an effect that was subsequently amplified by the GLM diet.
Article
Full-text available
A green-lipped mussel (GLM) preparation was evaluated in a randomized, double-controlled and double-blinded clinical trial. It was hypothesized that the treatment effect would be less than that of the positive control (carprofen) but more than that of the negative control (placebo). Forty-five dogs with chronic pain and a radiographic diagnosis of osteoarthritis that were randomly allocated into one of three groups completed the study. All dogs were fed the test products or placebo for 8 weeks. The dogs were evaluated four times, at 4-week intervals. Six different variables were assessed: veterinary-assessed mobility index, two force plate variables, owner-evaluated chronic pain index and pain as well as locomotion visual analogue scales (VASs). Intake of extra carprofen was also evaluated. A chi-squared and a Mann-Whitney test were used to determine significance between groups. When changed to dichotomous variables, there were more dogs in the GLM than in the placebo group that improved, according to veterinary-assessed mobility, owner-evaluated chronic pain index and pain VAS (P = 0.031, P = 0.025, P = 0.011, respectively). For the same three, the odds ratio and their confidence interval were over one. The extent of improvement was significantly different between the GLM and the control in veterinary-assessed mobility (P = 0.012) and pain VAS (P = 0.004). In conclusion, GLM alleviated chronic orthopedic pain in dogs although it was not as effective as carprofen. As no side-effects were detected, GLM may be beneficial in dogs e.g. when non-steroidal anti-inflammatory drugs cannot be used.
Article
Full-text available
To evaluate the efficacy and tolerance of an extract of green-lipped mussel (GLME) in the management of mild-to-moderate degenerative joint disease (DJD) in dogs. Eighty-one dogs presumptively diagnosed with DJD were treated orally daily with either GLME or a placebo for 56 days, in a double-blind, placebo-controlled study. In an uncontrolled open-label extension to the study, all dogs were treated with GLME for an additional 56 days (from Days 57-112). Clinical signs were subjectively scored by the owners, and findings of detailed musculoskeletal examinations were scored by one veterinarian. Efficacy was assessed from a qualitative comparison of the proportion of dogs with improved clinical signs, and a quantitative comparison of the scores of the musculoskeletal examinations, between groups. Haematological and biochemical analyses and reports by owners of possible adverse drug reactions were used to screen for evidence of toxicity. There was close agreement between assessments by the veterinarian and owners. The clinical signs of DJD in both GLME-treated and placebo groups improved significantly over baseline by Day 28; this improvement continued over the entire course of the study. There were no significant differences between groups on Day 28. On Day 56, a higher proportion of dogs in the GLME-treated group had improved clinical signs (p=0.018), and GLME-treated dogs had marginally better (p=0.053) musculoskeletal scores than dogs in the placebo group. The differences between the groups were no longer apparent by Day 112, by which time the former placebo group had been receiving GLME for 56 days in the open-label phase of the study. The proportion of dogs in the former placebo group that had improved by Day 112 (29/32; 91%) was significantly greater (p=0.012) than the proportion improved at Day 56 (15/37; 41%). No signs of toxicity were apparent. GLME had a beneficial effect on the clinical signs of dogs presumptively diagnosed with mild-to-moderate DJD. Long-term therapy may be required before improvement is apparent.
Article
The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University. Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome. All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks. Neurological grading, lameness scores and neurological examinations were evaluated before and after the administration of PCSO-524 for two and four weeks. Radiographic examinations were taken before and after the administration of PCSO-524 for four weeks. The results revealed that a large percentage of dogs experienced improvements in clinical lameness and owner preference although only a few dogs had better radiographic findings. Some of the dogs showed worse radiographic findings, whereas the clinical signs improved. Although the percentages of the improved clinical lameness between the two OA patient groups were high, but were not statistically and significantly different, the radiographic OA findings improved more in patients that had OA in the hip and shoulder joints than in patients that had OA in the stifle joints.
Article
P54FP is an extract of Indian and Javanese turmeric, Curcuma domestica and Curcuma xanthorrhiza respectively, which contains a mixture of active ingredients including curcuminoids and essential oils. A randomised, double-blind, placebo-controlled, parallel group clinical trial of P54FP as a treatment for osteoarthritis of the canine elbow or hip was conducted to assess its efficacy and safety. Sixty-one client-owned dogs with osteoarthritis were recruited through first-opinion practices and examined at a single centre. After a two-week wash-out period, they were randomly allocated to receive P54FP or a placebo orally twice daily for eight weeks, and were re-examined after four, six and eight weeks of treatment. The effectiveness of the treatment was assessed in terms of the peak vertical force (PVz) and vertical impulse of the affected limbs, as measured with a force platform, by clinical assessments of lameness and joint pain by the investigators, and overall assessments of the response to treatment by the investigators and the owners. The results from 25 P54FP-treated dogs and 29 placebo-treated dogs showed that there was no statistically significant difference between the groups in terms of the PVz of the affected limb. The investigators' overall assessment showed a statistically significant treatment effect in favour of P54FP (P=0.012), but the owners' assessment just failed to reach statistical significance (P=0.063). No serious adverse effects were recorded, but two P54FP-treated dogs and four placebo-treated dogs were withdrawn from the study because their condition deteriorated.
Article
This study evaluated the efficacy of green lipped mussel (GLM), added to a complete dry diet, for alleviating clinical signs of arthritis in dogs. A double-blind longitudinal study design was used with 31 mixed-breed dogs exhibiting varying degrees of arthritis. Each dog was evaluated by a veterinarian and joints were individually scored for degree of pain, swelling, crepitus, and reduction in range of movement. Summation of all scores for an individual dog comprised its total arthritis score. At baseline, dogs were randomly allocated to control and test groups. Both groups were fed the same base dry diet, to which 0.3% GLM powder was added for dogs in the test group. The change in total arthritis score by the end of 6 weeks showed there was significant improvement (P <.05) in the test group versus the control group. Significant improvements were also observed in joint pain and swelling scores in the test group. Changes in joint crepitus and range of joint movement were not significantly different between the test and control groups. These findings provide strong evidence that GLM incorporated into a complete dry diet can help alleviate arthritis symptoms in dogs.